ARVN
Price
$28.00
Change
+$1.10 (+4.09%)
Updated
Nov 6, 04:00 PM (EDT)
117 days until earnings call
SNDX
Price
$21.36
Change
+$1.67 (+8.48%)
Updated
Nov 6, 04:00 PM (EDT)
119 days until earnings call
Ad is loading...

ARVN vs SNDX

Header iconARVN vs SNDX Comparison
Open Charts ARVN vs SNDXBanner chart's image
Arvinas
Price$28.00
Change+$1.10 (+4.09%)
Volume$42.15K
CapitalizationN/A
Syndax Pharmaceuticals
Price$21.36
Change+$1.67 (+8.48%)
Volume$404.17K
CapitalizationN/A
View a ticker or compare two or three
ARVN vs SNDX Comparison Chart
Loading...
ARVN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ARVN vs. SNDX commentary
Nov 07, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a Hold and SNDX is a Buy.

COMPARISON
Comparison
Nov 07, 2024
Stock price -- (ARVN: $26.90 vs. SNDX: $19.69)
Brand notoriety: ARVN and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 53% vs. SNDX: 174%
Market capitalization -- ARVN: $1.85B vs. SNDX: $1.68B
ARVN [@Biotechnology] is valued at $1.85B. SNDX’s [@Biotechnology] market capitalization is $1.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $488.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • ARVN’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, SNDX is a better buy in the long-term than ARVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 5 TA indicator(s) are bullish while SNDX’s TA Score has 6 bullish TA indicator(s).

  • ARVN’s TA Score: 5 bullish, 5 bearish.
  • SNDX’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, SNDX is a better buy in the short-term than ARVN.

Price Growth

ARVN (@Biotechnology) experienced а -2.18% price change this week, while SNDX (@Biotechnology) price change was +3.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.70%. For the same industry, the average monthly price growth was +12.96%, and the average quarterly price growth was +11.17%.

Reported Earning Dates

ARVN is expected to report earnings on Mar 03, 2025.

SNDX is expected to report earnings on Mar 05, 2025.

Industries' Descriptions

@Biotechnology (+0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARVN($1.85B) has a higher market cap than SNDX($1.68B). SNDX YTD gains are higher at: -8.885 vs. ARVN (-34.645). SNDX has higher annual earnings (EBITDA): -263.84M vs. ARVN (-350.6M). ARVN has more cash in the bank: 1.12B vs. SNDX (432M). SNDX has less debt than ARVN: SNDX (1.13M) vs ARVN (1.5M). ARVN has higher revenues than SNDX: ARVN (161M) vs SNDX (3.5M).
ARVNSNDXARVN / SNDX
Capitalization1.85B1.68B110%
EBITDA-350.6M-263.84M133%
Gain YTD-34.645-8.885390%
P/E RatioN/AN/A-
Revenue161M3.5M4,600%
Total Cash1.12B432M260%
Total Debt1.5M1.13M133%
FUNDAMENTALS RATINGS
ARVN vs SNDX: Fundamental Ratings
ARVN
SNDX
OUTLOOK RATING
1..100
1760
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
8542
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
4757
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARVN's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for SNDX (87). This means that ARVN’s stock grew somewhat faster than SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (42) in the Biotechnology industry is somewhat better than the same rating for ARVN (85). This means that SNDX’s stock grew somewhat faster than ARVN’s over the last 12 months.

ARVN's SMR Rating (96) in the Biotechnology industry is in the same range as SNDX (97). This means that ARVN’s stock grew similarly to SNDX’s over the last 12 months.

ARVN's Price Growth Rating (47) in the Biotechnology industry is in the same range as SNDX (57). This means that ARVN’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for ARVN (100). This means that SNDX’s stock grew significantly faster than ARVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARVNSNDX
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 24 days ago
84%
Declines
ODDS (%)
Bearish Trend 28 days ago
80%
Bearish Trend 7 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Ad is loading...
ARVN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TEMWX17.770.26
+1.48%
Templeton World A
TROIX13.390.13
+0.98%
T. Rowe Price Overseas Stock I
JABYX10.56N/A
N/A
JHancock Global Environmental Opps C
FRBRX155.78N/A
N/A
Franklin Biotechnology Discovery R6
VPRDX15.63N/A
N/A
VY® Morgan Stanley Global Franchise R6

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with ABCL. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
+0.37%
ABCL - ARVN
55%
Loosely correlated
-5.88%
IPSC - ARVN
50%
Loosely correlated
+5.56%
CRBU - ARVN
49%
Loosely correlated
+9.40%
KYMR - ARVN
47%
Loosely correlated
+1.32%
AXON - ARVN
46%
Loosely correlated
+2.21%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with RCUS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+3.96%
RCUS - SNDX
49%
Loosely correlated
-1.74%
FOLD - SNDX
46%
Loosely correlated
+3.62%
RAPT - SNDX
45%
Loosely correlated
+7.93%
VCYT - SNDX
45%
Loosely correlated
+2.72%
OABI - SNDX
45%
Loosely correlated
+3.93%
More